The RVD chemotherapy regimen combines lenalidomide, bortezomib, and dexamethasone, and is recognized by the European Society for Medical Oncology in its guidelines as the current standard therapy for treating multiple myeloma (MM). Here, Katja Weisel, MD, from University Hospital Tubingen, Tubingen, Germany, reviews the clinical findings that look at RVD as a maintenance therapy over 2 years after patients have reached remission. Speaking from the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, Prof. Weisel impresses the overall survival benefit that was shown in patients treated with RVD, indicating that there is a clear need to continue maintenance therapy post-remission in order for patients to achieve measurable residual disease (MRD) negativity.
